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Impaired de novo NAD+ biosynthesis predisposes to acute kidney injury, and 
augmenting NAD+ metabolism with oral nicotinamide supplementation may 
prevent acute kidney injury. 
 
Over one fifth of all hospitalized patients develop acute kidney injury (AKI), a condition 
which has been defined as an abrupt decline in renal function. The incidence of AKI is 
highest in intensive care unit (ICU) patients (32%), and in patients undergoing cardiac 
surgery (24%).1 AKI-associated all-cause mortality occurs in 23% of hospitalized 
patients, and depending on its severity, AKI confers 3-7x increased risk of death.1 AKI 
that is severe enough to require renal replacement therapy (RRT, dialysis or kidney 
transplantation) occurs in 2.3% of all hospitalized patients, increasing the risk of death 
by 24-fold.1 As there is currently no effective therapy for preventing AKI, there is an 
urgent unmet medical need to discover novel renoprotective therapies for improving 
clinical outcomes in AKI patients.  
Nicotinamide adenine dinucleotide (NAD+) is a universal electron acceptor that plays 
an essential role in cellular energy metabolism, and adaptive stress responses.2 Its 
depletion has been recognized to be a fundamental feature of aging that predisposes 
to a wide range of age-related neurodegenerative,2 cardiac and renal diseases.3 In this 
issue of Nature Medicine, Mehr et al4 identify that impaired de novo NAD+ biosynthesis 
at quinolinate phosphoribosyltransferase (QPRT) predisposes to AKI, and results in 
elevated levels of urinary quinolinate/tryptophan (uQ/T), a potential novel biomarker 
for AKI.4 Furthermore, they demonstrate that oral nicotinamide supplementation, to 
augment renal NAD+ metabolism, was able to prevent AKI.4 
The authors first carried out an unbiased metabolomics screen of 204 urinary 
metabolites in a mouse model of AKI and identified elevated levels of urinary 
quinolinate, an intermediate in the de novo NAD+ biosynthetic pathway from 
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tryptophan. Transient renal ischemia, which induces AKI by causing glomerular injury, 
was shown in kidney tissue to reduce NAD+ content, increase quinolinate levels, and 
decrease gene expression of QPRT (the enzyme which converts quinolinate to 
nicotinic acid mononucleotide, a precursor of NAD+).  
The authors further confirmed the role of QPRT deficiency in the development of AKI 
by showing that mice partially deficient in QPRT have elevated levels of urinary 
quinolinate under baseline conditions, even when this was normalized to urinary 
tryptophan levels (expressed as uQ/T), and were found to be more susceptible to AKI 
following transient renal ischemia. Interestingly, administration of nicotinamide (a 
precursor of NAD+) prior to renal ischemia made them less prone to develop AKI, 
suggesting that augmentation of renal NAD+ metabolism was renoprotective.  
Next, the authors investigated whether impaired de novo NAD+ biosynthesis linked to 
QPRT also occurs during transient renal ischemia in adult patients undergoing cardiac 
surgery. AKI occurs in 24% of adult patients undergoing cardiac surgery,1 with modest 
rises in post-operative serum creatinine being associated with higher 30-day 
mortality,5,6 and AKI patients requiring RRT having in-hospital mortality rates as high 
as 60%.7 In a small cohort of 6 patients undergoing cardiac surgery on 
cardiopulmonary bypass who developed post-operative AKI, the authors 
demonstrated that uQ/T increased significantly at 24 hours and persisted for 5 days 
following surgery, when compared to 6 patients who underwent cardiac surgery but 
did not develop AKI. In a separate large prospective study of 215 ICU patients, the 
authors found that elevations in urinary quinolinate and uQ/T occurred at a median of 
2.5 days prior to the diagnosis of AKI. Importantly, levels of uQ/T were able to identify 
patients at risk of developing AKI, and predict adverse clinical outcomes (severe AKI, 
RRT- and AKI-related death, and in-hospital death). These findings suggest that a 
deficient QPRT may contribute to the development of AKI in humans, and that uQ/T 
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may be a novel biomarker for detection of AKI and for prediction of adverse outcomes 
in ICU patients.  
The authors next tested the safety and tolerability of oral nicotinamide administration 
in human volunteers. A 3-day course of high dose (3gm/day) oral nicotinamide was 
well-tolerated, led to detectable levels of circulating nicotinamide, and was not 
nephrotoxic (as it did not affect kidney function) in a small group of healthy volunteers 
(n=8). They went on to carry out a Phase 1 randomized controlled trial of oral 
nicotinamide versus placebo in adults undergoing cardiac surgery to assess its safety 
and tolerability. The study comprised 3 treatment groups: nicotinamide at two doses 
and placebo (n=14), administered orally or via a nasogastric tube on days -1, 0, and 
+1 the day before, the day of and the day after surgery. Blood and urine nicotinamide 
levels were significantly higher in patients receiving nicotinamide, and the side-effect 
profile was no different to placebo. Although this study was not designed to test efficacy 
of nicotinamide, the latter did significantly reduce post-operative levels of serum 
cardiac troponin-T and serum creatinine levels over the 3-day post-operative period, 
suggesting a potential cardioprotective and renoprotective effect.  
The findings from the study by Mehr et al 4 suggest that reduced levels of kidney NAD+ 
due to impaired de novo NAD+ biosynthesis at QPRT predisposes to AKI (Figure 1). 
Further studies are needed to elucidate the mechanisms through which kidney levels 
of QPRT are reduced following the acute insult. uQ/T may be a novel biomarker for 
identification of patients at risk of AKI, and it may also predict adverse clinical outcomes 
in ICU patients. Further work is needed to assess the robustness of uQ/T as a 
biomarker for early detection of AKI and for predicting adverse clinical outcomes, and 
to investigate how its performance as a biomarker compares with other AKI biomarkers 
such as neutrophil gelatinase-associated lipocalin.8 Finally, administration of oral 
nicotinamide, to augment renal NAD+ metabolism, is safe and tolerable in cardiac 
surgery patients, and has the therapeutic potential to be renoprotective. Whether, 
5 
 
nicotinamide can prevent AKI and improve clinical outcomes in cardiac surgery and 
ICU patients, needs to be investigated in large adequately powered randomized 
clinical trials. Nicotinamide may be a promising and low-cost therapy for not only 
preventing AKI, as it may also have the therapeutic potential to protect other organs 
against acute injury such as the heart (in acute myocardial infarction), brain (following 
stroke) and liver (during hepatic surgery).  
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Figure 1: The study by Mehr et al.4 provides 3 key findings for patients at risk of 
developing acute kidney injury (AKI). The authors have uncovered a new mechanism 
underlying AKI, by identifying in kidneys subjected to transient ischemia that reduced 
levels of quinolinate phosphoribosyltransferase (QPRT) result in impaired renal de 
novo biosynthesis of NAD+, and predispose to AKI. This metabolic defect increased 
levels of urinary quinolate/tryptophan, providing a potential novel biomarker for 
identifying patients at risk of AKI, and for predicting adverse clinical outcomes. Finally, 
the authors have demonstrated that augmenting renal NAD+ metabolism with oral 
nicotinamide (a precursor of NAD+) could prevent AKI, providing a potential novel 
therapy for preventing AKI and improving clinical outcomes in patients admitted to ICU 
or undergoing cardiac surgery.     
 
 
 
 
